ImmunoGen signs ADC deal with ImmunoBiochem
引进/卖出免疫疗法上市批准抗体药物偶联物加速审批
Massachusetts-based ImmunoGen and Toronto-based ImmunoBiochem have inked a multi-target license and option agreement to advance novel, first-in-class ADCs.
The collaboration will combine ImmunoGen’s proprietary linker and payload technologies with ImmunoBiochem’s antibodies directed against specific targets.
ImmunoBiochem has developed novel ADCs and immunostimulatory antibody-drug conjugates (ISACs) based on novel cancer secretome target biology with efficacy in intractable solid tumors, including triple-negative breast cancer and pancreatic cancer.
ImmunoGen holds the most recent FDA approval in the ADC space with Elahere, which was granted accelerated approval last November for FRα-positive ovarian, fallopian tube or primary peritoneal cancerFRα-positive ovarian, fallopian tube or primary peritoneal cancer. The drugmaker recently announced additional phase 3 data that supports its mission to make Elahere the new standard of care for patients with FRα-positive platinum-resistant ovarian cancerFRα-positive platinum-resistant ovarian cancer.
Big ticket deals in the ADC space are on the rise, with the most notable being Pfizer's $43 billion acquisition of Seagen. On the collaboration front, Eisai and BlissBio recently announced a clinical trial collaboration agreement worth up to $2 billion. While the financial details of the ImmunoGen-ImmunoBiochem deal were not disclosed, ImmunoGen will pay ImmunoBiochem an upfront fee in exchange for an exclusive license to existing antibodies directed against a specific undisclosed target. ImmunoBiochem will be eligible to receive milestone payments and royalties.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
适应症
靶点
药物
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。